Hims & Hers Health, Inc.
HealthcareNYSE:HIMS · New York Stock Exchange
-$2.05 today
Vol 16.37M · Avg 28.06M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
23.7%
avg 8.0%
ROIC
6.0%
avg -28.4%
ROA
6.0%
avg -20.0%
Analysis
ROE is currently the strongest return metric at 23.7% versus its period average of 8.0%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mohamed ElShenawy | Chief Technology Officer | $3.65M | — | 51 | $376,222.00 | 0.17% |
Andrew Dudum | Co-Founder, Chairman & Chief Executive Officer | $1.32M | — | 38 | $887,684.00 | 0.40% |
Oluyemi Okupe | Chief Financial Officer | $925,119.00 | — | 40 | $262,954.00 | 0.12% |
Mike Chi | Chief Operating Officer | $828,914.00 | — | 46 | $407,282.00 | 0.18% |
Soleil Teubner Boughton | Chief Legal Officer & Corporate Secretary | $772,440.00 | — | 48 | $299,368.00 | 0.13% |
Irene A. Becklund | Senior Vice President, Controller & Principal Accounting Officer | $361,125.00 | — | 42 | $8,752.00 | <0.01% |
Deborah Autor | Chief Policy Officer & Director | $119,000.00 | — | 59 | $493,792.00 | 0.22% |
Patrick Carroll | Chief Medical Officer & Director | $40,000.00 | — | 68 | $435.00 | <0.01% |
Kathryn H. Beiser | Chief Communications Officer | — | — | — | — | — |
Sarah Stuart | Senior Vice President of People | — | — | — | — | — |
Peter Stahl | Senior Vice President of Men's Reproductive & Sexual Health | — | — | — | — | — |
William James Newby | Senior Director of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$1.17M
Sells
42
$27.99M
Net Sentiment
$26.82M
Net selling
Most Active
Okupe Oluyemi
15 transactions
1–10 of 43
Analysis
Insiders reported 1 buys worth $1.17M and 42 sells worth $27.99M over the last 12 months. That adds up to net selling of $26.82M. Okupe Oluyemi was the most active insider with 15 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +80.3% | +25.2% (7yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +80.3% over three years. Forward estimates point to Revenue at +25.2% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Moderna, Inc.
NASDAQ:MRNA
$19.80B
Penumbra, Inc.
NYSE:PEN
$12.54B
Align Technology, Inc.
NASDAQ:ALGN
$12.52B
Revvity, Inc.
NYSE:RVTY
$11.12B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.81B
Baxter International Inc.
NYSE:BAX
$10.77B
The Ensign Group, Inc.
NASDAQ:ENSG
$8.73B
Bio-Techne Corporation
NASDAQ:TECH
$8.45B
Qiagen N.V.
NYSE:QGEN
$7.64B
HealthEquity, Inc.
NASDAQ:HQY
$7.39B
Who manages HIMS?
Hims & Hers Health, Inc. (HIMS) lists 12 active executives. The top listed executive is Kathryn H. Beiser, Chief Communications Officer.
Are HIMS insiders buying or selling?
Recent insider activity shows net selling of $65.82M.
Explore More
Continue the stock analysis
Jump to another research area for this company.